TiumBio Co., Ltd. (KOSDAQ:321550)

South Korea flag South Korea · Delayed Price · Currency is KRW
5,500.00
-70.00 (-1.26%)
At close: Jan 27, 2026
43.23%
Market Cap182.28B
Revenue (ttm)9.32B +21.5%
Net Income-11.73B
EPS-441.55
Shares Out29.02M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume181,817
Average Volume171,814
Open5,570.00
Previous Close5,570.00
Day's Range5,290.00 - 5,680.00
52-Week Range2,900.00 - 9,450.00
Beta0.44
RSI57.20
Earnings DateMar 19, 2026

About TiumBio

TiumBio Co., Ltd., a drug discovery company, researches and develops therapeutics for patients with unaddressed rare diseases. The company’s products pipeline includes chemical entity-based drugs and biopharmaceuticals comprising NCE401, NCE403, NCE406, and NBP604. It has a collaboration agreement with Oncodesign Société Anonyme for the research and development of fibrosis drug candidates. The company was founded in 2016 and is based in Seongnam-si, South Korea. [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 2016
Country South Korea
Stock Exchange KOSDAQ
Ticker Symbol 321550
Full Company Profile

Financial Performance

In 2024, TiumBio's revenue was 6.79 billion, an increase of 38.65% compared to the previous year's 4.90 billion. Losses were -20.64 billion, 15.3% more than in 2023.

Financial Statements